In the Treatment of Metastatic Colorectal Cancer

Drugs

Volumn 64, Issue 1, 2004, Pages 109-118

  Reynolds, Neil A ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; TOPOTECAN; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ACNE; ADVERSE DRUG REACTION; ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; GENE OVEREXPRESSION; HUMAN; HYPERSENSITIVITY REACTION; LEUKOPENIA; METASTASIS; NAUSEA; NEUTROPENIA; RASH; REVIEW; TUMOR GROWTH; TUMOR REGRESSION; VOMITING; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; HUMANS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE;

EID: 1642533527     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464010-00007     Document Type: Review

References (52)

1. American Cancer Society. Cancer statistics 2003 [online]. Available from URL: http://www.cancer.org [Accessed 2003 Aug 14]
2. Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 2000 Sep; 321: 531-5
3. Labianca RF, Beretta GD, Pessi MA. Colorectal cancer: disease management considerations. Drugs 2001; 61 (12): 1751-64
4. Labianca R, Pessi MA, Zamparelli G. Treatment of colorectal cancer: current guidelines and future prospects for drug therapy. Drugs 1997 Apr; 53 (4); 593-607
5. Midgley R, Kerr D. Colorectal cancer. Lancet 1999 Jan; 353: 391-9
6. Adjei AA. A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br J Clin Pharmacol 1999 Sep; 48: 265-77
7. Chau I, Cunningham D. Oxaliplatin for colorectal cancer in the United States: better late than never. J Clin Oncol 2003 Jun; 21 (11): 2049-51
8. Karapetis CS, Yip D, Harper PG. The treatment of metastatic colorectal cancer. Int J Clin Pract 1999 Jun; 53 (4): 287-94
9. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000 Mar; 355: 1041-7
10. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000 Sep; 343 (13): 905-14
11. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000 Aug; 18 (16): 2938-47
12. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil- leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000 Jan; 18 (1): 136-47
13. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 2001 Sep; 37 Suppl. 4: S16-22
14. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001 Nov; 13 (6): 506-13
15. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60 Suppl. 1: 15-23; discussion 41-2
16. Ciardiello F, Tortora G. Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Investig Drugs 2002 Jun; 11 (6): 755-68
17. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 2000; 60 Suppl. 1: 25-32; discussion 41-2
18. Kang X, Patel D, Shi J, et al. Anti-EGFR monoclonal antibody cetuximab binds the EGFR variant III receptor and internalizes phosphorylated receptor on the cell surface [abstract no. 498]. Eur J Cancer 2002 Nov; 38 Suppl. 7: S149
19. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999 Apr; 59 (8): 1935-40
20. Ciardiello F, Damiano V, Bianco R, et al. Antitumour activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst 1996 Dec; 88 (23): 1770-6
21. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000 Sep; 6: 3739-47
22. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999 Feb; 5: 257-64
23. Matsumoto T, Perrotte P, Bar-Eli M, et al. Blockade of EGF-R signalling with anti-EGF-R monoclonal antibody (Mab) C225 inhibits matrix metalloproteinase-9 (MMP-9) expression and invasion of human transitional cell carcinoma (TCC) in vitro and in vivo [abstract no. 565]. 89th Annual Meeting of the American Association for Cancer Research; 1998 Mar 28-Apr 1; New Orleans
24. Prewett MC, Hooper AT, Bassi R, et al. Enhanced Antitumor Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody IMC-C225 in Combination with Irinotecan (CPT-11) against Human Colorectal Tumor Xenografts. Clin Cancer Res 2002 May; 8 (5): 994-1003
25. Prewett MC, Hooper AT, Bassi R, et al. Enhanced antitumour activity of anti-epidermal growth factor receptor monoclonal antibody ERBITUX™ (IMC-C225) in combination with irinotecan (CPT-11), 5-FU, and leucovorin against human colorectal carcinoma xenografts [abstract no. 2878]. 93rd Annual Meeting of the American Association for Cancer Research; 2002 Apr 6-10; San Francisco
26. Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor-receptor monoclonal antibody C225. Clin Cancer Res 1999 Apr; 5: 909-16
27. Shaheen RM, Ahmad SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001 Aug 17; 85 (4): 584-9
28. Bianco C, Bianco R, Tortora G, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 2000 Nov; 6: 4343-50
29. Bianco C, Tortora G, Caputo R, et al. Antitumour activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor targeted therapies [abstract no. 133]. Ann Oncol 2001; 12 Suppl. 4: 93
30. Delbaldo C, Pierga JY, Dieras V, et al. Evaluation of the pharmacokinetic (PK) interactions between cetuximab and irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing advanced solid tumours. Results of a phase I study [abstract no. 552]. Eur J Cancer Suppl 2003 Sep; 1 (5): S167
31. Folprecht G, Lutz MP, Schoeffski P, et al. Pharmacokinetic (PK) evaluation of cetuximab in combination with weekly irinotecan (CPT-11) and 24h infusional 5-FU/folinic acid (FA) as first line treatment in patients (pts) with epidermal growth factor receptor (EGFR)-positive metastatic colorectal cancer (MCRC) [abstract no. 890]. Proc Am Soc Clin Oncol 2003; 22: 222
32. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000 Feb; 18 (4): 904-14
33. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001 Jul 1; 19 (13): 3234-43
34. Falcey J, Pfister D, Cohen R, et al. A study of anti-epidermal growth factor receptor monoclonal antibody C225 and cisplatin in patients with head and neck or lung carcinomas [abstract no. 1364]. Proc Am Soc Clin Oncol 1997 May; 16: 383a
35. Anderson V, Cooper M, O'Chei E, et al. Dose dependent pharmacokinetics of a chimerized monoclonal antibody (C225) against EGFr [abstract no. 3561]. 89th Annual Meeting of the American Association for Cancer Research; 1998 Mar 28-Apr 1; New Orleans
36. Cooper MR, Cohen R, Anderson V, et al. Pharmacokinetics of a chimerized monoclonal antibody (C225) against the epidermal growth factor receptor (EGFr) [abstract no. 834]. Proc Am Soc Clin Oncol 1998 May; 17: 216a
37. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002 Mar 1; 94 (5): 1593-611
38. Kim ES, Mauer AM, Tran HT, et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report [abstract no. 2581]. Proc Am Soc Clin Oncol 2003 May; 22: 642
39. Raoul JL, Van Laethem JL, Mitry E, et al. Phase II study of cetuximab combined with FOLFIRI (bi-weekly irinotecan plus infusional 5-FU and folinic acid (FA)) in patients (pts) with metastatic, Epidermal Growth Factor Receptor (EGFR)-expressing colorectal cancer (CRC) [abstract no. 289]. Eur J Cancer Suppl 2003 Sep; 1 (5): S89
40. Rosenberg AH, Loehrer PJ, Needle MN, et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil and leucovorin in colorectal cancer that expresses the epidermal growth factor receptor [abstract no. 536]. 38th Annual Meeting of the American Society of Clinical Oncology; 2002 May 18-21; Orlando
41. Schöffski P, Lutz C-H, Folprecht G, et al. Cetuximab (C225, Erbitux) in combination with irinotecan, infusional 5-fluorouracil and folinic acid is safe and active in patients with metastatic colorectal cancer expressing epidermal growth factor receptor. Results of a phase I study [abstract no. 495]. Eur J Cancer 2002; 38 Suppl. 7: S148-9
42. Cunningham D, Humblet Y, Siena S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor positive, irinotecan-refractory metastatic colorectal cancer [abstract no. 1012]. Proc Am Soc Clin Oncol 2003 May; 22: 252 plus oral presentation
43. Saltz L, Meropol NJ, Loehrer PJ, et al. Single agent IMC-C225 (Erbitux) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR) [abstract no. 504]. Proc Am Soc Clin Oncol 2002 May; 21 (1): 127
44. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer that expresses epidermal growth factor receptor [abstract no. 7]. Proc Am Soc Clin Oncol 2001 May; 20 (1): 3a
45. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981 Jan; 47 (1): 207-14
46. Van Cutsem E, Gascón Vilaplana P, Seitz JF, et al. Cetuximab in a randomized phase II trial as a single agent or in combination with irinotecan in patients with Epidermal Growth Factor Receptor (EGFR)-expressing, irinotecan-refractory metastatic colorectal cancer (CRC). Eur J Cancer Suppl 2003 Sep; 1 (5): S325
47. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001 Jun; 144: 1169-76
48. Kimyai-Asadi A, Jih MH. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors [letter]. Arch Dermatol 2002 Jan; 138 (1): 129-31
49. Cohen RB, Falcey JW, Paulter VJ, et al. Safety profile of the monoclonal antibody IMC-C225, an anti-epidermal growth factor receptor (EGFr) used in the treatment of EGFr-positive tumors [abstract no. 1862]. Proc Am Soc Clin Oncol 2000 May; 19: 474
50. Hollywood E. Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225. Semin Oncol Nurs 2002 May; 18 (2 Suppl. 2): 30-5
51. Khazaeli MB, LoBuglio AF, Falcey JW, et al. Low immunogenicity of a chimeric monoclonal antibody (MoAb), IMC-C225, used to treat epidermal growth factor receptor-positive tumours [abstract no. 808]. Proc Am Soc Clin Oncol 2000 May; 19: 207a
52. Merck KGaA. Merck KGaA: Erbitux cancer drug approved and available in Switzerland [online]. Available from URL: http:// me.merck.de [Accessed 2003 Dec 8]